{"id":23145,"date":"2025-01-26T14:35:09","date_gmt":"2025-01-26T06:35:09","guid":{"rendered":"https:\/\/flcube.com\/?p=23145"},"modified":"2025-01-26T14:35:12","modified_gmt":"2025-01-26T06:35:12","slug":"nhsa-targets-low-volume-drugs-in-national-reimbursement-list","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23145","title":{"rendered":"NHSA Targets Low-Volume Drugs in National Reimbursement List"},"content":{"rendered":"\n<p>The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs that are included in the National Reimbursement Drug List (NRDL) but have seen little trade volume. The move aims to ensure the basic medication needs of insured patients by monitoring the production and supply of these underutilized drugs. According to the NHSA, some of these drugs have not been traded on provincial pharmaceutical procurement platforms for extended periods or have low trading volumes. Others have been marked as &#8220;discontinued&#8221; in the national medical insurance information business coding standard database for a long time.<\/p>\n\n\n\n<p><strong>NHSA&#8217;s Requirements for MAHs<\/strong><br>To address these issues, the NHSA has required the marketing authorization holders (MAHs) of the drugs on the &#8220;List&#8221; to submit an enterprise commitment letter and a drug basic information form. These documents should include relevant explanatory materials. MAHs are instructed to mail the hard copies of these documents to the NHSA before February 28, 2025. Additionally, they must send the electronic version of the complete set of materials to the designated email address: jczxypc@nhsa.gov.cn.<\/p>\n\n\n\n<p><strong>Implications and Next Steps<\/strong><br>This initiative by the NHSA underscores the importance of ensuring the availability and accessibility of essential medications for insured patients. By monitoring the production and supply of low &#8211; volume drugs, the administration aims to prevent potential shortages and ensure that patients can continue to receive the treatments they need. MAHs are expected to comply with these requirements to maintain the integrity of the NRDL and support the broader goals of China&#8217;s healthcare system.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs&#8230;<\/p>\n","protected":false},"author":1,"featured_media":23146,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[92,67],"class_list":["post-23145","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-bmi","tag-nhsa-prev-smia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NHSA Targets Low-Volume Drugs in National Reimbursement List - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs that are included in the National Reimbursement Drug List (NRDL) but have seen little trade volume. The move aims to ensure the basic medication needs of insured patients by monitoring the production and supply of these underutilized drugs. According to the NHSA, some of these drugs have not been traded on provincial pharmaceutical procurement platforms for extended periods or have low trading volumes. Others have been marked as &quot;discontinued&quot; in the national medical insurance information business coding standard database for a long time.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23145\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NHSA Targets Low-Volume Drugs in National Reimbursement List\" \/>\n<meta property=\"og:description\" content=\"The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs that are included in the National Reimbursement Drug List (NRDL) but have seen little trade volume. The move aims to ensure the basic medication needs of insured patients by monitoring the production and supply of these underutilized drugs. According to the NHSA, some of these drugs have not been traded on provincial pharmaceutical procurement platforms for extended periods or have low trading volumes. Others have been marked as &quot;discontinued&quot; in the national medical insurance information business coding standard database for a long time.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23145\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-26T06:35:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-26T06:35:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2610-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"605\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23145#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23145\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NHSA Targets Low-Volume Drugs in National Reimbursement List\",\"datePublished\":\"2025-01-26T06:35:09+00:00\",\"dateModified\":\"2025-01-26T06:35:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23145\"},\"wordCount\":269,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23145#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2610-png.avif\",\"keywords\":[\"BMI\",\"NHSA (prev. SMIA)\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23145#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23145\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23145\",\"name\":\"NHSA Targets Low-Volume Drugs in National Reimbursement List - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23145#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23145#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2610-png.avif\",\"datePublished\":\"2025-01-26T06:35:09+00:00\",\"dateModified\":\"2025-01-26T06:35:12+00:00\",\"description\":\"The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs that are included in the National Reimbursement Drug List (NRDL) but have seen little trade volume. The move aims to ensure the basic medication needs of insured patients by monitoring the production and supply of these underutilized drugs. According to the NHSA, some of these drugs have not been traded on provincial pharmaceutical procurement platforms for extended periods or have low trading volumes. Others have been marked as \\\"discontinued\\\" in the national medical insurance information business coding standard database for a long time.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23145#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23145\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23145#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2610-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2610-png.avif\",\"width\":1080,\"height\":605,\"caption\":\"NHSA Targets Low-Volume Drugs in National Reimbursement List\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23145#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NHSA Targets Low-Volume Drugs in National Reimbursement List\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NHSA Targets Low-Volume Drugs in National Reimbursement List - Insight, China&#039;s Pharmaceutical Industry","description":"The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs that are included in the National Reimbursement Drug List (NRDL) but have seen little trade volume. The move aims to ensure the basic medication needs of insured patients by monitoring the production and supply of these underutilized drugs. According to the NHSA, some of these drugs have not been traded on provincial pharmaceutical procurement platforms for extended periods or have low trading volumes. Others have been marked as \"discontinued\" in the national medical insurance information business coding standard database for a long time.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23145","og_locale":"en_US","og_type":"article","og_title":"NHSA Targets Low-Volume Drugs in National Reimbursement List","og_description":"The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs that are included in the National Reimbursement Drug List (NRDL) but have seen little trade volume. The move aims to ensure the basic medication needs of insured patients by monitoring the production and supply of these underutilized drugs. According to the NHSA, some of these drugs have not been traded on provincial pharmaceutical procurement platforms for extended periods or have low trading volumes. Others have been marked as \"discontinued\" in the national medical insurance information business coding standard database for a long time.","og_url":"https:\/\/flcube.com\/?p=23145","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-26T06:35:09+00:00","article_modified_time":"2025-01-26T06:35:12+00:00","og_image":[{"width":1080,"height":605,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2610-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23145#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23145"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NHSA Targets Low-Volume Drugs in National Reimbursement List","datePublished":"2025-01-26T06:35:09+00:00","dateModified":"2025-01-26T06:35:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23145"},"wordCount":269,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=23145#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2610-png.avif","keywords":["BMI","NHSA (prev. SMIA)"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23145#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23145","url":"https:\/\/flcube.com\/?p=23145","name":"NHSA Targets Low-Volume Drugs in National Reimbursement List - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=23145#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=23145#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2610-png.avif","datePublished":"2025-01-26T06:35:09+00:00","dateModified":"2025-01-26T06:35:12+00:00","description":"The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs that are included in the National Reimbursement Drug List (NRDL) but have seen little trade volume. The move aims to ensure the basic medication needs of insured patients by monitoring the production and supply of these underutilized drugs. According to the NHSA, some of these drugs have not been traded on provincial pharmaceutical procurement platforms for extended periods or have low trading volumes. Others have been marked as \"discontinued\" in the national medical insurance information business coding standard database for a long time.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23145#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23145"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=23145#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2610-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2610-png.avif","width":1080,"height":605,"caption":"NHSA Targets Low-Volume Drugs in National Reimbursement List"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23145#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NHSA Targets Low-Volume Drugs in National Reimbursement List"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2610-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23145"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23145\/revisions"}],"predecessor-version":[{"id":23147,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23145\/revisions\/23147"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/23146"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}